Edesa Biotech today reported #financialresults for fiscal year 2025 $EDSA https://t.co/bsQbwL4G71

Edesa’s #Phase3 study of paridiprubart in patients with #ARDS met its primary and secondary endpoints, showing demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. $EDSA #biotech #drugdevelopment https://t.co/02XG2JFhZY

Edesa to participate in the @HCWCO 27th Annual Global Investment Conference next week in New York #HCWConference #vitiligo #ARDS $EDSA

Edesa Biotech today reported #financialresults for fiscal 3Q 2025 $EDSA https://t.co/vj40QITj61

Edesa Biotech is a proud sponsor and supporter of World #Vitiligo Day and this year’s theme “Innovation for Every Skin” #WVD2025 #biotechnology #CXCL10 $EDSA https://t.co/UM0SbgaJnJ

Edesa Biotech today reported #financialresults for fiscal 2Q 2025 $EDSA https://t.co/2R1QWH7nTs

Edesa to join the annual Bloom Burton Healthcare Investor #Conference next week. $EDSA #vitiligo #BBHIC2025 https://t.co/7Xwjrdgp3C

Edesa is pleased to announce that Peter Weiler will assume the role of CFO on May 1. Peter is a veteran of the #pharma and #biotech sectors, with extensive experience in finance and corporate strategy. https://t.co/uJ5mHY9iF8

Congratulations to the Global #Vitiligo Foundation for hosting a great scientific symposium this week at #AAD2025. Edesa is proud to provide support for advancing research, education and collaboration within the vitiligo community.

Edesa Biotech today reported #financialresultsfor fiscal 1Q 2025 #vitiligo #ACD #ARDS #fibrosis $EDSA https://t.co/4tm7q6xGVe

Edesa Biotech Announces $15m private placement led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insiders. https://t.co/sfcAK1mfjB

Edesa Biotech today reported #financialresults for FY 2024 #vitiligo #ACD #ARDS #fibrosis $EDSA https://t.co/PqUmKVPiDJ

$EDSA announced today that the company’s CEO & Founder, Dr. Par Nijhawan, will invest up to $5 million in Edesa, including an immediate investment of ~$1.5 million. >> https://t.co/HEO4TAtqnQ #vitiligo #ACD #ARDS #fibrosis #biotech

Edesa Biotech will be participating in #BIOEurope next week, Nov 4-6. Reach out to our team ahead of the event in the partnering system or at https://t.co/IYBEjEvUlU #vitiligo #fibrosis #ARDS #dermatitis

Edesa Biotech today reported #financialresults for the 3rd quarter of FY 2024 #vitiligo #dermatitis #ARDS #fibrosis $EDSA https://t.co/GnNW25Fz5w

Par Nijhawan, CEO of Edesa Biotech, shares his thoughts on the recent BARDA announcement and what this means for the Company moving forward. $EDSA

We’ve selected host-directed therapeutics from @EdesaBiotech and InflaRx for inclusion in a phase 2 platform clinical trial to address acute respiratory distress syndrome (#ARDS). Learn more: https://t.co/eNiIDaej9o

BARDA selects #paridiprubart for U.S. funded platform trial in general #ARDS $EDSA https://t.co/uahhafL2w5

Listen as Par Nijhawan, CEO of Edesa Biotech, shares an exciting company update and overview of the upcoming clinical calendar. https://t.co/prEDGwnHer

Edesa Biotech today reported #financialresults for the 2nd quarter of FY 2024 #vitiligo #pulmonaryfibrosis #ARDS #ACD $EDSA https://t.co/EHmeNa84P2